Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. METHODS: The C...

Descripción completa

Detalles Bibliográficos
Autores principales: Rådholm, Karin, Figtree, Gemma, Perkovic, Vlado, Solomon, Scott D., Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Barrett, Terrance D., Shaw, Wayne, Desai, Mehul, Matthews, David R., Neal, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075881/
https://www.ncbi.nlm.nih.gov/pubmed/29526832
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075881/
https://www.ncbi.nlm.nih.gov/pubmed/29526832
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222

Ejemplares similares